MedTrace Logo

Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers

NCT04795414 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1370

Last updated 2021-03-19

No results posted yet for this study

Summary

With the unprecedented morbidity of the COVID-19 pandemic, the vaccine effectiveness needs to be assessed across diverse populations. The purpose of this study is to evaluate the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in medical workers.

Conditions

Interventions

BIOLOGICAL

SARS-CoV-2 Vaccine(Vero Cell), Inactivated

The subjects of Vaccination Group will receive two doses, 21 days apart of inactivated SARS-CoV-2 vaccine (4 μg of BBIBP-CorV)

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Erzhen Chen · Ruijin Hospital

  • Xinxin Zhang · Ruijin Hospital

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-14
Primary Completion
2022-04-30
Completion
2023-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04795414 on ClinicalTrials.gov